Clinical Trial Update: Study Of The Safety And Pharmacokinetics Of CE-326,597 In Patients With Asymptomatic Gallstones [Phase 1]

View source ↗

Summary

Phase 1 study evaluating safety and pharmacokinetics of the compound CE-326,597 in patients with asymptomatic gallstones has completed. The report highlights sa…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cholelithiasis

Drugs mentioned

• CE-326,597 (CE-326,597)

Snippet

Sponsor: Pfizer | Conditions: Obesity | Phase 1 | Status: COMPLETED